A word from the CEO
" It is with great pleasure that I present this year's results. The year has been characterized by continuous and strong sales growth. We have increased our sales by over 33% compared to the previous year. This marks the fourth consecutive year of stable sales growth, with a clear focus on achieving profitability. During the fourth quarter, we finally achieved both a positive EBITDA result and positive cash flow. The company is now well on its way toward sustainable profitability, while we continue to see strong order intake.
In summary, 2024 has been a successful year, marked by strong sales growth, strategic partnerships, and significant research findings. We look forward with confidence to continued expansion and development, where strong order intake in our existing markets, combined with opportunities in new markets, provides a solid foundation for the future.
With great optimism and high ambition, we enter 2025 with the goal of building on our successes and continuing our journey toward long-term, sustainable profitability."
Anders Hultman, CEO
Reporting period October 1st - December 31st
· Net sales amounted to KSEK 15,364 (9,511).
· Profit after financial items amounted to KSEK -8,997 (-17,136)*.
· Cash flow from operating activities for the period amounted to KSEK 3,250 (-912).
· Earnings per share before and after dilution amounted to SEK -0,04 (-0,07) SEK.
· Cash and cash equivalents at the end of the period amounted to KSEK 47,785 (50,723).
· EBITDA for the quarter amounted to KSEK 964 (-5,940).
* Includes costs for goodwill amortization of KSEK 9,895 (9,895) for the quarter.
Reporting period January 1st - December 31st
· Net sales amounted to KSEK 57,436 (43,039).
· Profit after financial items amounted to KSEK -42,449 (-59,297)*.
· Cash flow from operating activities for the period amounted to KSEK -2,358 (-13,436).
· Earnings per share before and after dilution amounted to SEK -0,18 (-0,26).
· Cash and cash equivalents at the end of the period amounted to KSEK 47,785 (50,723).
· EBITDA for the period amounted to KSEK -323 (-14,184).
* Includes costs for goodwill amortization of KSEK 39,578 (39,578) for the period.
Highlights
Revenue Increases
Revenue increased by 62% during the quarter compared to the same quarter last year and by 33% for the full year compared to the previous year.
On the path to long-term profitability
Positive net earnings excluding goodwill amortization during the fourth quarter.
Strengthened market presence
A strategic partnership with a leading Japanese IVD company has been established, significantly strengthening the company's market presence in China.
Focus on growth and business development
The company is now conducting a strategic review with a focus on growth and business development. Our strong cash position enables
Interim report January 1st - December 31st, 2024 (Link)
The composition of the nomination committee for AroCell's annual general meeting 2025, has changed due to Greg Dingizian's decision to resign after Agartha AB sold its shareholding to Labbex Förvaltnings AB. Didrik Hamilton, who represents direct holdings and holdings via companies, will replace him as a member of the nomination committee.
Contacts
Anders Hultman, CEO
Phone: +46 (0) 8 799 67 50
E-mail: anders.hultman@arocell.com
About AroCell
AroCell AB (publ) is a Swedish company that develops and markets blood and urine sample tests. The corporation specializes in oncology and bacteriology. The company has a broad product portfolio, used in healthcare, and established in various markets. In oncology, AroCell uses various biomarkers, TK1, and cytokeratins, to support the treatment of various cancers such as breast, prostate, and bladder cancers. AroCell's product portfolio also includes a rapid bacteriological test for a simple and safe diagnosis of typhoid fever. AroCell (AROC) is listed on Nasdaq First North Growth Market with Redeye AB as company's Certified Adviser. For more information; www.arocell.com
This information is information that AroCell is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-02-19 08:00 CET.
